Cellular therapies for the endometrium: An update

Acta Obstetricia Et Gynecologica Scandinavica
Suzanna QueckbörnerKristina Gemzell-Danielsson

Abstract

An update on the current state of endometrial cell therapies in terms of cell types, mechanisms of action, delivery, safety, regulatory frameworks and future perspectives. This review focuses on clinical trials using angiogenesis-promoting therapies and stromal therapies piloted in the last 10 years for alleviating Asherman's syndrome and long-term infertility. All studies present promising preliminary results, indicating increased endometrial thickness and resumed menstruation. Further characterization of individual cell products, their mode of action and larger clinical trials will be essential to establishing cell therapy as a viable option for the treatment of infertility and fertility preservation.

References

May 10, 1991·European Journal of Obstetrics, Gynecology, and Reproductive Biology·P M StarkeyM C Rees
Dec 1, 1986·Clinical Obstetrics and Gynecology·W Shaffer
Dec 1, 1966·American Journal of Obstetrics and Gynecology·A FoixB Lema
Feb 10, 2004·Biology of Reproduction·Rachel W S ChanCaroline E Gargett
Jun 19, 2004·Journal of Obstetrics and Gynaecology : the Journal of the Institute of Obstetrics and Gynaecology·H Yasmin, J H Adeghe
Jan 1, 2008·Obstetrics and Gynecology·Scott C GoodwinUNKNOWN Fibroid Registry for Outcomes Data (FIBROID) Registry Steering Committee and Core Site Investigators
Apr 15, 2008·Fertility and Sterility·Dan YuTin-Chiu Li
May 13, 2008·Lancet·Katarina Le BlancUNKNOWN Developmental Committee of the European Group for Blood and Marrow Transplantation
Apr 27, 2012·Archives of Gynecology and Obstetrics·Neena MalhotraSuneeta Mittal
Mar 19, 2014·American Journal of Reproductive Immunology : AJRI·Carolina von GrothusenParameswaran G Lalitkumar
Sep 6, 2014·Journal of Human Reproductive Sciences·Neeta SinghSona Dharmendra
Dec 19, 2014·Frontiers in Immunology·Olivier G De JongMarianne C Verhaar
Aug 9, 2015·Human Reproduction Update·Jacqueline A Maybin, Hilary O D Critchley
Feb 24, 2017·Health Economics, Policy, and Law·Theodore Marmor, Michael K Gusmano
Mar 16, 2017·Stem Cells Translational Medicine·Reinhold J MedinaAlan W Stitt
Mar 24, 2017·JBRA Assisted Reproduction·Shahrzad ZadehmodarresLeila Nazari
Oct 28, 2017·Stem Cells Translational Medicine·Rebekah M SamsonrajSimon M Cool
Nov 17, 2017·Science Translational Medicine·Antonio GalleuFrancesco Dazzi
Feb 6, 2018·Cytotherapy·Marina V KovinaAlexey V Lyundup
Feb 13, 2018·Cytotherapy·Katarina Le Blanc, Lindsay C Davies
Jun 5, 2018·Current Women's Health Reviews·Petra A B Klemmt, Anna Starzinski-Powitz
Jul 31, 2018·Journal of Tissue Engineering and Regenerative Medicine·Verónica ÁlvarezJavier G Casado
Nov 1, 2014·Therapeutic Innovation & Regulatory Science·Akinori HaraYasuyuki Sahara
Nov 16, 2018·Nature·Roser Vento-TormoSarah A Teichmann

❮ Previous
Next ❯

Citations

Jun 10, 2020·Updates in Surgery·Elena Puente GonzaloAntonio Simone Laganà
Jan 8, 2020·Stem Cell Research & Therapy·Suzanna QueckbörnerLindsay C Davies
Mar 3, 2021·Cell and Tissue Research·Neda KeyhanvarRalf Dittrich
Jun 3, 2021·International Journal of Molecular Sciences·Wen-Ling LeePeng-Hui Wang
Jun 10, 2021·Cell Transplantation·Yiyin GaoLianwen Zheng

❮ Previous
Next ❯

Related Concepts

Related Feeds

CREs: Gene & Cell Therapy

Gene and cell therapy advances have shown promising outcomes for several diseases. The role of cis-regulatory elements (CREs) is crucial in the design of gene therapy vectors. Here is the latest research on CREs in gene and cell therapy.

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.

Related Papers

Nederlandsch tijdschrift voor verloskunde en gynaecologie
A M SchellenM M Couckuyt
© 2022 Meta ULC. All rights reserved